GW Pharmaceuticals PLC Sponsored ADR(NASDAQ : GWPH)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Loading GWPH News...
Health Technology » Pharmaceuticals Other
|VRX||Valeant Pharmaceuticals International, Inc.||-1.06%||10.75||9.9%||$288.61m|
|PRGO||Perrigo Co. Plc||-0.29%||67.96||4.8%||$175.25m|
|SHPG||Shire PLC Sponsored ADR||0.70%||175.23||0.3%||$161.02m|
|ENDP||Endo International Plc||-0.20%||9.97||8.9%||$127.59m|
|JAZZ||Jazz Pharmaceuticals Plc||0.45%||143.14||1.9%||$87.29m|
|UTHR||United Therapeutics Corporation||0.66%||140.05||11.5%||$84.42m|
|PRXL||PAREXEL International Corporation||0.86%||62.35||6.7%||$69.81m|
|PCRX||Pacira Pharmaceuticals, Inc.||-0.11%||46.90||16.9%||$64.97m|
|PTLA||Portola Pharmaceuticals, Inc.||0.55%||38.44||10.3%||$48.16m|
|ICPT||Intercept Pharmaceuticals, Inc.||0.80%||116.73||22.8%||$46.26m|
|HZNP||Horizon Pharma plc||-1.31%||14.37||9.7%||$45.60m|
|GWPH||GW Pharmaceuticals PLC Sponsored ADR||0.04%||121.17||9.9%||$39.52m|
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development, and Pipeline Research & Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.